

# Nabis Holdings Inc.

11:25 25 Jun 2019

## Nabis Holdings completes stake in hot Israeli cannabis tech company Cannova Medical

Nabis Holdings Inc (CSE:NAB), a cannabis investment company, said Tuesday that it has completed the acquisition of a 49% stake in Cannova Medical Ltd., which has a patented cannabis delivery technology platform.

The Vancouver cannabis investment company bought 2,260,500 shares representing a tidy 49% stake in Cannova Medical.

Nabis retains the option to acquire the remaining 51% of Cannova. If it decides to exercise that interest, Nabis must make a nominal cash payment and issue an additional 7.4 million shares to Cannova shareholders, held in escrow and subject to certain performance milestones.

Israel-based Cannova Medical's line of cannabis sublingual strips overcome delivery and dosing challenges, providing easy-to-use, non-smoke solutions for consuming different types of cannabis or CBD formulations. Cannova's controlled release oral thin films lead to dosing accuracy, enhanced efficacy, and safety in the delivery of cannabinoids.

"Our goal for strategic investments at Nabis is to enter multiple aspects of the cannabis sector including related technology," said Nabis Holdings CEO Shay Shnet. "We are thrilled to have closed our 49% interest acquisition enabling the Cannova team to bring this disruptive technology to market at an increased pace."

**READ:** Nabis Holdings makes strategic stake in Israeli cannabis consumables company

Cannova is also developing the NovaJet Pro, an innovative, counter-top machine that enables clients to create customized film strips in the convenience of their homes. With the NovaJet, clients will be able to receive accurate and tailored sublingual strips with specific measured quantities of cannabinoids and other natural substances.

According to the purchase agreement, Nabis will enjoy exclusive distribution rights to both Cannova's sublingual strips, as well as the company's NovaJet printing machine. The products will be marketed to both the recreational and medical markets.

"The combination of cannabis with smart and innovative technology is key to the future of both medical and recreational cannabis usage," said Cannova Medical founder CEO Omri Schanin. "We are excited to work with the Nabis team leveraging their extensive experience and capabilities to help us reach our growth goals faster."


In addition to the US and international cannabis sector, Nabis Holdings invests in assets across multiple industries, including real property, securities and cryptocurrency.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

**Price:** 0.095

**Market Cap:** \$10.39 m

### 1 Year Share Price Graph



November 2018 May 2019 November 20

### Share Information

**Code:** NAB

**Listing:** CSE

**52 week High Low**  
0.98 0.06

**Sector:** Investments and investor services

**Website:** [www.nabisholdings.com](http://www.nabisholdings.com)

### Company Synopsis:

*Nabis Holdings is a Canadian investment issuer that invests in high quality cash flowing assets across multiple industries, including real property, securities, cryptocurrency, and all aspects of the U. S. and international cannabis sector. Led by two of the co-founders of MPX Bioceutical, one of the largest takeovers in the U. S.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nabis Holdings Inc. named herein, including the promotion by the Company of Nabis Holdings Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).